Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period - PubMed (original) (raw)
Review
doi: 10.2169/internalmedicine.50.4079. Epub 2011 May 1.
Johji Kato, Noriaki Kawano, Yuki Yoshimura, Hiroyuki Masuyama, Takashi Fukunaga, Yuichiro Sato, Haruhiko Maruyama, Kenroh Mihara, Akira Ueda, Kiyokazu Toyoda, Takuroh Imamura, Kazuo Kitamura
Affiliations
- PMID: 21532219
- DOI: 10.2169/internalmedicine.50.4079
Free article
Review
Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period
Sayaka Kawano et al. Intern Med. 2011.
Free article
Abstract
Background: Eosinophilic myocarditis is a rare clinical entity characterized by eosinophilia and myocardial inflammation with infiltrating eosinophils. The prognosis of patients with eosinophilic myocarditis is difficult to determine due the disease's rarity and varied causes; consequently, standard treatment has not been established.
Objective: To elucidate the clinical characteristics and treatment outcome of eosinophilic myocarditis, we retrospectively studied 7 patients fulfilling the criteria of the Japanese Circulation Society for eosinophilic myocarditis from among 64 patients admitted to our institution with eosinophilia over a 27-year period.
Results: The patients' ages at diagnosis ranged from 36 to 83 years (median: 52 years). The etiologies of the eosinophilic myocarditis were found to be idiopathic (3 patients), Churg-Strauss syndrome (2 patients), parasitic infection (1 patient) and chronic eosinophilic leukemia (CEL) (1 patient). In addition to treatment for the underlying disease, we also administered prednisolone at a dose appropriate to the disease severity (6 of 7 patients). The patient who was diagnosed with a parasitic infection was treated only with albendazole, because eosinophilic myocarditis was mild. The patient with CEL was positive for the FIP1 L1-PDGFRα fusion gene and was treated with imatinib. Eosinophilic cationic protein was a useful marker for assessing disease activity and treatment efficacy. At the end of the study, of the seven patients treated, six were alive (86%), giving a mean survival time of 37 ± 40 months (mean ± SD).
Conclusion: Because eosinophilic myocarditis has various etiologies, it is essential to identify the etiology of the underlying disease. In the majority of eosinophilic myocarditis patients, administration of prednisolone may be an effective therapeutic modality producing a good outcome.
Similar articles
- Eosinophilic myocarditis due to Churg-Strauss syndrome with markedly elevated eosinophil cationic protein.
Hara T, Yamaguchi K, Iwase T, Kadota M, Bando M, Ogasawara K, Bando S, Ise T, Niki T, Ueda Y, Tomita N, Taketani Y, Yamada H, Soeki T, Wakatsuki T, Sata M. Hara T, et al. Int Heart J. 2013;54(1):51-3. doi: 10.1536/ihj.54.51. Int Heart J. 2013. PMID: 23428926 - Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature.
Chaudhry MA, Grazette L, Yoon A, Correa A, Fong MW. Chaudhry MA, et al. Curr Hypertens Rev. 2019;15(1):8-12. doi: 10.2174/1573402114666180903164900. Curr Hypertens Rev. 2019. PMID: 30179138 Review. - [Eosinophilic myopericarditis revealing a Churg-Strauss syndrome].
Daumas A, Bernard F, Jacquier A, Rossi P, Francès Y, Granel B. Daumas A, et al. Rev Med Interne. 2011 May;32(5):323-4; author reply 325. doi: 10.1016/j.revmed.2011.02.019. Epub 2011 Mar 22. Rev Med Interne. 2011. PMID: 21429636 French. No abstract available. - [Complicated course of Churg-Strauss syndrome with eosinophilic perimyocarditis and pericardial tamponade].
Lamparter S, Pankuweit S, Kölsch S, Maisch B. Lamparter S, et al. Dtsch Med Wochenschr. 2004 Oct 8;129(41):2173-6. doi: 10.1055/s-2004-831861. Dtsch Med Wochenschr. 2004. PMID: 15457397 German. - [Ten questions about eosinophilic myocarditis].
Pagura L, Imazio M, Merlo M, Sinagra G. Pagura L, et al. G Ital Cardiol (Rome). 2022 Apr;23(4):259-267. doi: 10.1714/3766.37535. G Ital Cardiol (Rome). 2022. PMID: 35343477 Review. Italian.
Cited by
- Cardiomegaly and Low Voltage Suggest Cardiac Involvement in a Patient With Hypereosinophilic Syndrome: A Case Report.
Kashima K, Ooi M, Yoshishige Y, Kawabata K. Kashima K, et al. Cureus. 2023 May 22;15(5):e39354. doi: 10.7759/cureus.39354. eCollection 2023 May. Cureus. 2023. PMID: 37362537 Free PMC article. - Diagnosis and treatment of eosinophilic myocarditis.
Zhong Z, Yang Z, Peng Y, Wang L, Yuan X. Zhong Z, et al. J Transl Autoimmun. 2021 Sep 2;4:100118. doi: 10.1016/j.jtauto.2021.100118. eCollection 2021. J Transl Autoimmun. 2021. PMID: 35005589 Free PMC article. Review. - Successful Bridge-to-Recovery Treatment in a Young Patient with Fulminant Eosinophilic Myocarditis: Roles of a Percutaneous Ventricular Assist Device and Endomyocardial Biopsy.
Hasegawa-Tamba S, Sugi K, Gatate Y, Sugiyama K, Muramatsu T, Nishimura S, Yasuda M, Fukushima K, Nakano S. Hasegawa-Tamba S, et al. Case Rep Emerg Med. 2019 Jul 2;2019:8236735. doi: 10.1155/2019/8236735. eCollection 2019. Case Rep Emerg Med. 2019. PMID: 31355017 Free PMC article. - Use of Emergency Department Extracorporeal Membrane Oxygenation for Treatment of Acute Necrotizing Myocarditis.
Loner CA, Crane PW. Loner CA, et al. Clin Pract Cases Emerg Med. 2019 Jan 4;3(1):47-50. doi: 10.5811/cpcem.2018.11.40569. eCollection 2019 Feb. Clin Pract Cases Emerg Med. 2019. PMID: 30775664 Free PMC article. - Severe eosinophilic myocarditis associated with modafinil in a patient with normal peripheral eosinophil count.
Bäuml M, Udi J, Klingel K, Bode C, Warnatz K, Zirlik A, Duerschmied D, Biever P. Bäuml M, et al. Clin Res Cardiol. 2019 Aug;108(8):963-966. doi: 10.1007/s00392-019-01434-w. Epub 2019 Feb 12. Clin Res Cardiol. 2019. PMID: 30756153 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical